Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Examining Persistence in Smokers With Schizophrenia

15. januar 2019 oppdatert av: Marc L. Steinberg, Ph.D., Rutgers, The State University of New Jersey
All participants will receive free weekly counseling (8- weeks) and free nicotine patches (10-weeks). They will complete assessment measures commonly used in smoking cessation studies. We hope to show that this treatment is feasible in this small pilot study before comparing it to a more established treatment in a future randomized clinical trial.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This study is a non-randomized trial of a new psychosocial treatment for smoking cessation (for smokers with schizophrenia) that is based on cognitive behavioral therapy for smoking cessation - a commonly used approach. Participants will receive free weekly counseling (8- weeks) and free nicotine patches (10-weeks). They will complete assessment measures commonly used in smoking cessation studies. We hope to show that this treatment is feasible in this small pilot study before comparing it to a more established treatment in a future randomized clinical trial.

Studietype

Intervensjonell

Registrering (Faktiske)

27

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • New Jersey
      • New Brunswick, New Jersey, Forente stater, 08901
        • Rutgers Robert Wood Johnson Medical School

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 64 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Must be between 18 - 64 years old
  • Must indicate commitment to quitting smoking in the next 30 days
  • Must smoke at least 5 cigarettes per day for past 6-months
  • Expired breath carbon monoxide (CO) > 5 to ensure daily cigarette use
  • Must score < 8 (or <7 for women) on the Alcohol Use Disorders Identification Test
  • Must score less than 3 on the 6-month Drug Abuse Screening Test-10
  • Must provide a negative urine drug screen for cannabis, cocaine, opiates, or
  • methamphetamine (Note: Participants with a positive screen for opiates may
  • participate with proof of prescription for opiates.)
  • Must have a diagnosis of Schizophrenia or Schizoaffective Disorder on Structured Clinical Interview
  • Psychiatric illness must be stable, as indicated by no hospitalizations in previous 8 weeks, and a stable psychotropic medication regimen including a stable antipsychotic dose for 8 weeks

Exclusion Criteria:

  • Must not be currently receiving tobacco dependence treatment counseling
  • Must not currently be taking varenicline (Chantix)
  • Must not be taking bupropion (Zyban/Wellbutrin) to quit smoking
  • Must not be taking any nicotine preparations (gum, lozenge, patch, spray, inhaler) daily over the last 10 days.
  • Must not report unstable angina pectoris, myocardial infarction, or significant cardiac arrhythmia (including atrial fibrillation) in the past 90 days
  • Must not be pregnant, breastfeeding, or planning on becoming pregnant in the next 4-months. Women who can become pregnant may be included if using effective birth control
  • Must not have pending legal matters with potential to result in jail time
  • Must not be planning on moving outside local area in next 3-months

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Persistence Targeted Smoking Cessation
8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
Atferdsmessig: counseling
individual, weekly, smoking cessation counseling + over-the-counter nicotine patch

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Task Persistence - Mirror Tracing
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
Number of seconds persisting on a computerized mirror tracing task (Higher number of seconds = greater persistence)
Through end-of-treatment - approximately 8 weeks after baseline
Task Persistence - Sustained Divided Attention Task
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
Seconds persisting on Sustained Divided Attention Task (Higher number of seconds = greater persistence)
Through end-of-treatment - approximately 8 weeks after baseline
Task Persistence - Breath-holding
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
Number of seconds persisting on a breath-holding endurance task (Higher number of seconds = greater persistence)
Through end-of-treatment - approximately 8 weeks after baseline
Task Persistence -Temperament and Character Inventory-Persistence Scale (TCI-P)
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
Score on Temperament and Character Inventory-Persistence Scale (TCI-P) (Higher score = greater persistence)
Through end-of-treatment - approximately 8 weeks after baseline
Task Persistence - 2-item Task Persistence Measure
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
Score on 2-item Task Persistence Measure (Higher score = greater persistence)
Through end-of-treatment - approximately 8 weeks after baseline
Task Persistence - Distress Tolerance Scale (DTS)
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
Score on Distress Tolerance Scale (DTS) (Higher score = greater persistence)
Through end-of-treatment - approximately 8 weeks after baseline
Task Persistence - Thoughts About Smoking Questionnaire
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
Score on the Thoughts About Smoking Questionnaire (Higher score = less persistence)
Through end-of-treatment - approximately 8 weeks after baseline
Self-reported ratings of ease of understanding and helpfulness of counseling
Tidsramme: Through end-of-treatment - approximately 8 weeks after baseline
percentage of participants who rate the intervention as "easy to understand" and "helpful"
Through end-of-treatment - approximately 8 weeks after baseline

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Rutgers, The State University of New Jersey

Samarbeidspartnere

National Institute on Drug Abuse (NIDA)

Etterforskere

  • Hovedetterforsker: Marc L Steinberg, Ph.D., Rutgers, The State University of New Jersey

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. januar 2017

Primær fullføring (Faktiske)

13. juni 2018

Studiet fullført (Faktiske)

13. juni 2018

Datoer for studieregistrering

Først innsendt

3. november 2017

Først innsendt som oppfylte QC-kriteriene

14. november 2017

Først lagt ut (Faktiske)

17. november 2017

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. januar 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. januar 2019

Sist bekreftet

1. januar 2019

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 20150001885
  • R21DA041163-01 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

Nei

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på counseling

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Colombia

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

Abonnere